Advertisement Banner
  • Home
  • News
  • Medicine
  • Health Tech
  • Health Living
  • Contact
  • Privacy Policy
No Result
View All Result
  • Home
  • News
  • Medicine
  • Health Tech
  • Health Living
  • Contact
  • Privacy Policy
No Result
View All Result
HealthNews
No Result
View All Result
Home Medicine

Pfizer Seeks Approval for Oral COVID-19 Antiviral Paxlovid

admin by admin
July 4, 2022
in Medicine


The New Drug Application (NDA) for Paxlovid™ has been submitted to the Food and Drug Administration (FDA). Pfizer is seeking approval of the oral antiviral therapy for both vaccinated and unvaccinated patients who are at high risk for progression to severe illness from COVID-19.

Paxlovid consists of nirmatrelvir and low-dose ritonavir. Nirmatrelvir inhibits the viral replication of SARS-CoV-2 by blocking the activity of the SARS-CoV-2 3CL protease. Coadministration with low-dose ritonavir slows the metabolism of nirmatrelvir and prolongs its activity.

The NDA includes data from the phase 2/3 EPIC-HR study (ClinicalTrials.gov Identifier: NCT04960202), which compared the efficacy and safety of Paxlovid to placebo in patients with a laboratory-confirmed SARS-CoV-2 infection within a 5-day period with mild to moderate symptoms. Results from the final Clinical Study Report showed Paxlovid reduced the risk of hospitalization or death from any cause by 86% in patients treated within 5 days of symptom onset compared with placebo (P <.0001).


Continue Reading

The submission also includes data from the EPIC-SR study (ClinicalTrials.gov Identifier: NCT05011513), which enrolled standard risk individuals who had a confirmed diagnosis of SARS-CoV-2 infection within 5 days prior to randomization; onset of symptoms within 5 days of randomization; and at least 1 characteristic or underlying medical condition associated with an increased risk of developing severe illness and were fully vaccinated against COVID-19 or, no characteristics associated with an increased risk of severe COVID-19 and were unvaccinated. Among 1153 patients enrolled through December 2021, treatment with Paxlovid showed a nonsignificant 51% relative risk reduction in hospitalization or death. Among 721 vaccinated adults with at least 1 risk factor, treatment with Paxlovid showed a nonsignificant 57% relative risk reduction.

An integrated analysis of data across both studies showed an 84% reduction (P <.0001) in hospitalizations or death, compared with placebo and regardless of vaccination status, in patients with at least 1 risk factor for progression to severe COVID-19 illness who were treated with Paxlovid within 5 days of symptom onset. Viral load reduction was also observed to be consistent across all studies.

The application also includes safety data from more than 3500 patients treated with Paxlovid in clinical trials as well as postauthorization experiences. With regard to “COVID-19 rebound”, the data showed that the frequency of return of detectable nasal viral RNA following treatment was low and generally similar between the treatment and placebo groups.

“Data from our clinical development program, coupled with the more than 1.7 million patients around the world who have been prescribed our oral treatment to date, reinforce Paxlovid as an important treatment option for mild to moderate COVID-19 in patients at greater risk of progression to severe symptoms, regardless of vaccination status,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “We look forward to working with the FDA toward full regulatory approval for Paxlovid.”

Reference

Pfizer announces submission of New Drug Application to the US FDA for Paxlovid™. News release. June 30, 2022. https://www.businesswire.com/news/home/20220630005126/en/Pfizer-Announces-Submission-of-New-Drug-Application-to-the-U.S.-FDA-for-PAXLOVID%E2%84%A2

This article originally appeared on MPR



Source link

Advertisement Banner
Previous Post

Bio Farma, ConnectedLife, Fitbit and Google Cloud develop new platform to encourage Indonesians to live healthier

Next Post

New Leukemia Treatment Drug Could Make Cancer Cells More Susceptible To Chemo

Next Post

New Leukemia Treatment Drug Could Make Cancer Cells More Susceptible To Chemo

Discussion about this post

Recommended

Lesion Swab Samples Should Be Used to Test for Monkeypox

4 weeks ago

Women Could Live Longer And Better With Improved Diet, Study Suggests

1 month ago

Don't Miss

AIIMS’ AI-based website for dyslexia offers fresh hope, Health News, ET HealthWorld

August 14, 2022

How Does Polio Spread?

August 14, 2022

Chewing Xylitol Gum Can Promote Earlier Bowel Function After Cesarean Delivery

August 14, 2022

Bodyport receives FDA 510(k) for connected scale

August 14, 2022

© 2022 Pharma News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy.

Navigate Site

  • News
  • Medicine
  • Health Tech
  • Health Tech
  • Health Living
  • Contact
  • Privacy Policy

Newsletter Sign Up.

No Result
View All Result
  • Home
  • News
  • Medicine
  • Health Tech
  • Health Living
  • Contact
  • Privacy Policy

© 2022 JNews - Premium WordPress news & magazine theme by Jegtheme.